4.6 Article

Mini-hemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge

Journal

NPJ VACCINES
Volume 3, Issue -, Pages -

Publisher

SPRINGERNATURE
DOI: 10.1038/s41541-018-0063-7

Keywords

-

Ask authors/readers for more resources

Seasonal vaccines are currently the most effective countermeasure against influenza. However, seasonal vaccines are only effective against strains closely related to the influenza strains contained in the vaccine. Recently a new hemagglutinin (HA) stem-based antigen, the so-called mini-HA, has been shown to induce a cross-protective immune response in influenza-naive mice and non-human primates (NHP). However, prior exposure to influenza can have a profound effect on the immune response to subsequent influenza infection and the protective efficacy of vaccination. Here we show that mini-HA, compared to a trivalent influenza vaccine (TIV), elicits a broadened influenza-specific humoral immune response in NHP previously exposed to influenza. Serum transfer experiments showed that antibodies induced by both mini-HA and seasonal vaccine protected mice against lethal challenge with a H1N1 influenza strain heterologous to the H1 HA included in the TIV. However, antibodies elicited by mini-HA showed an additional benefit of protecting mice against lethal heterosubtypic H5N1 influenza challenge, associated with H5 HA-specific functional antibodies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Correction Multidisciplinary Sciences

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques (vol 586, pg 583, 2020)

Noe B. Mercado, Roland Zahn, Frank Wegmann, Carolin Loos, Abishek Chandrashekar, Jingyou Yu, Jinyan Liu, Lauren Peter, Katherine McMahan, Lisa H. Tostanoski, Xuan He, David R. Martinez, Lucy Rutten, Rinke Bos, Danielle van Manen, Jort Vellinga, Jerome Custers, Johannes P. Langedijk, Ted Kwaks, Mark J. G. Bakkers, David Zuijdgeest, Sietske K. Rosendahl Huber, Caroline Atyeo, Stephanie Fischinger, John S. Burke, Jared Feldman, Blake M. Hauser, Timothy M. Caradonna, Esther A. Bondzie, Gabriel Dagotto, Makda S. Gebre, Emily Hoffman, Catherine Jacob-Dolan, Marinela Kirilova, Zhenfeng Li, Zijin Lin, Shant H. Mahrokhian, Lori F. Maxfield, Felix Nampanya, Ramya Nityanandam, Joseph P. Nkolola, Shivani Patel, John D. Ventura, Kaylee Verrington, Huahua Wan, Laurent Pessaint, Alex Van Ry, Kelvin Blade, Amanda Strasbaugh, Mehtap Cabus, Renita Brown, Anthony Cook, Serge Zouantchangadou, Elyse Teow, Hanne Andersen, Mark G. Lewis, Yongfei Cai, Bing Chen, Aaron G. Schmidt, R. Keith Reeves, Ralph S. Baric, Douglas A. Lauffenburger, Galit Alter, Paul Stoffels, Mathai Mammen, Johan Van Hoof, Hanneke Schuitemaker, Dan H. Barouch

Summary: A correction to this paper has been published.

NATURE (2021)

Article Medicine, General & Internal

A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine

Nadine C. Salisch, Kathryn E. Stephenson, Kristi Williams, Freek Cox, Leslie van der Fits, Dirk Heerwegh, Carla Truyers, Marrit N. Habets, Diane G. Kanjilal, Rafael A. Larocca, Peter Abbink, Jinyan Liu, Lauren Peter, Carlos Fierro, Rafael A. De la Barrera, Kayvon Modjarrad, Roland C. Zahn, Jenny Hendriks, Conor P. Cahill, Maarten Leyssen, Macaya Douoguih, Johan van Hoof, Hanneke Schuitemaker, Dan H. Barouch

Summary: The clinical study on the vaccine candidate Ad26.ZIKV.001 for ZIKV showed good safety and immunogenicity in healthy adult volunteers, making it a promising candidate for future development if the need reemerges.

ANNALS OF INTERNAL MEDICINE (2021)

Article Cell Biology

A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques

Xuan He, Malika Aid, Abishek Chandrashekar, Jingyou Yu, Katherine McMahan, Frank Wegmann, Catherine Jacob-Dolan, Jenny S. Maron, Caroline Atyeo, Huahua Wan, Daniel Sellers, Jinyan Liu, Michelle Lifton, Sarah Gardner, Esther A. Bondzie, Julia Barrett, Kunza Ahmad, Tochi Anioke, Jake Yalley-Ogunro, Jeanne Muench, Adrienne Goode, Hanne Andersen, Mark G. Lewis, Galit Alter, Hanneke Schuitemaker, Roland Zahn, Dan H. Barouch

Summary: This study found that single-shot Ad26.COV2.S immunization in rhesus macaques resulted in durable immune responses, including binding and neutralizing antibodies, memory B cells, and long-lasting plasma cells. Boosting with Ad26.COV2.S or Ad26.COV2.S.351 significantly increased the humoral and cellular immune responses, which were highly cross-reactive against multiple SARS-CoV-2 variants. The modified Ad26.COV2.S.351 vaccine showed slightly higher immune responses against specific variants.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Article Immunology

Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models

Eirikur Saeland, Leslie van der Fits, Renske Bolder, Marjolein Heemskerk-van der Meer, Joke Drijver, Yolinda van Polanen, Cornelis Vaneman, Lisanne Tettero, Jan Serroyen, Hanneke Schuitemaker, Benoit Callendret, Johannes P. M. Langedijk, Roland C. Zahn

Summary: This study compares the qualitative differences in immune responses induced by two vaccine platforms and finds that the adenoviral vector-based vaccine elicits superior immune responses compared to the subunit vaccine in small animal models, which has implications for the development of respiratory syncytial virus (RSV) vaccines.

VACCINE (2022)

Article Immunology

Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice

Shant H. Mahrokhian, Lisa H. Tostanoski, Catherine Jacob-Dolan, Roland C. Zahn, Frank Wegmann, Katherine McMahan, Jingyou Yu, Makda S. Gebre, Esther A. Bondzie, Huahua Wan, Olivia Powers, Tianyi Ye, Julia Barrett, Hanneke Schuitemaker, Dan H. Barouch

Summary: A single immunization with Ad26.COV2.S vaccine induces durable antibody responses in mice, with an increasing neutralizing capacity against SARS-CoV-2 delta and beta variants over time. Spike-specific antibody-secreting cells were found in the bone marrow and spleen, suggesting long-term immunity.

NPJ VACCINES (2022)

Article Immunology

Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters

Lisa H. Tostanoski, Abishek Chandrashekar, Shivani Patel, Jingyou Yu, Catherine Jacob-Dolan, Aiquan Chang, Olivia C. Powers, Daniel Sellers, Sarah Gardner, Julia Barrett, Owen Sanborn, Kathryn E. Stephenson, Jessica L. Ansel, Kate Jaegle, Michael S. Seaman, Maciel Porto, Megan Lok, Brittany Spence, Kathleen Cayer, Danielle Nase, Shaikim Holman, Heath Bradette, Swagata Kar, Hanne Andersen, Mark G. Lewis, Freek Cox, Jeroen T. B. M. Tolboom, Anne Marit de Groot, Dirk Heerwegh, Mathieu Le Gars, Jerald Sadoff, Frank Wegmann, Roland C. Zahn, Hanneke Schuitemaker, Dan H. Barouch

Summary: This study directly explores the protective efficacy of human antibodies elicited by Ad26.COV2.S vaccination through adoptive transfer studies. The results suggest that purified antibodies from vaccinated individuals can provide dose-dependent protection in recipient animals, and this protection is correlated with the binding and neutralizing potency of the antibodies.

NPJ VACCINES (2022)

Article Immunology

Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels

Machteld M. Tiemessen, Laura Solforosi, Liesbeth Dekking, Dominika Czapska-Casey, Jan Serroyen, Nancy J. Sullivan, Ariane Volkmann, Maria Grazia Pau, Benoit Callendret, Hanneke Schuitemaker, Kerstin Luhn, Roland Zahn, Ramon Roozendaal

Summary: The Marburg and Sudan viruses, belonging to the filovirus family, cause aggressive diseases with high mortality rates. A two-dose heterologous vaccine regimen (Ad26.Filo, MVA-BN-Filo) has been shown to provide fully protective immune responses against Marburg virus, Sudan virus, and Ebola virus in non-human primates. The vaccine-induced glycoprotein-binding antibodies remain stable for over a year, suggesting the regimen as a potential prophylactic vaccination strategy against filovirus outbreaks.

VACCINES (2022)

Article Microbiology

An introduction to the Marburg virus vaccine consortium, MARVAC

Robert W. Cross, Ira M. Longini, Stephan Becker, Karin Bok, David Boucher, Miles W. Carroll, Janet Diaz, William E. Dowling, Ruxandra Draghia-Akli, James T. Duworko, John M. Dye, Michael A. Egan, Patricia Fast, Amy Finan, Courtney Finch, Thomas R. Fleming, Joan Fusco, Thomas W. Geisbert, Anthony Griffiths, Stephan Guenther, Lisa E. Hensley, Anna Honko, Ruth Hunegnaw, Jocelyn Jakubik, Julie Ledgerwood, Kerstin Luhn, Demetrius Matassov, Jeffrey Meshulam, Emily Nelson, Christopher L. Parks, Roxana Rustomjee, David Safronetz, Lauren M. Schwartz, Dean Smith, Paul Smock, Ydrissa Sow, Christina F. Spiropoulou, Nancy J. Sullivan, Kelly L. Warfield, Daniel Wolfe, Courtney Woolsey, Roland Zahn, Ana Maria Henao-Restrepo, Cesar Munoz-Fontela, Andrea Marzi

Summary: This article discusses the current progress, challenges, and future directions of MARV vaccines, as well as the formation of the MARVAC consortium to respond to the threat of this infectious disease.

PLOS PATHOGENS (2022)

Review Immunology

Cell entry and innate sensing shape adaptive immune responses to adenovirus-based vaccines

Sonia Marquez-Martinez, Aneesh Vijayan, Selina Khan, Roland Zahn

Summary: Nonreplicating adenovirus-based vectors are effective prophylactic vaccines against infectious viral diseases, inducing protective cellular and humoral responses. Differences in cellular entry or endosomal escape mechanisms contribute to differences in innate immune sensing between adenovirus species. Understanding these early events is critical for developing vaccines that elicit effective and durable adaptive immune responses with acceptable reactogenicity.

CURRENT OPINION IN IMMUNOLOGY (2023)

Article Immunology

Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets

Selina Khan, Nadine C. Salisch, Ana Izquierdo Gil, Satish Boedhoe, Karin Feddes-de Boer, Jan Serroyen, Hanneke Schuitemaker, Roland C. Zahn

Summary: The study investigated the impact of vaccine-elicited immunity to Ad26 vector-based vaccines on antigen-specific immune responses induced by subsequent vaccinations against different disease targets. The results showed that there were no consistent differences in immune responses against the target pathogens in animals vaccinated with homologous and heterologous Ad26 vector-based vaccine regimens, supporting the sequential use of these vaccines targeting different diseases.

NPJ VACCINES (2022)

Article Immunology

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

Viki Bockstal, Maarten Leyssen, Dirk Heerwegh, Bart Spiessens, Cynthia Robinson, Jeroen N. Stoop, Ramon Roozendaal, Thierry Van Effelterre, Auguste Gaddah, Griet A. Van Roey, Laura Solforosi, Roland Zahn, Benoit Callendret, Jenny Hendriks, Kerstin Luhn, Macaya Douoguih, Hanneke Schuitemaker, Johan Van Hoof

Summary: This study extrapolated the protective effect of an Ebola vaccine from animals to humans using immunologic markers and calculated the predicted survival probability. Using a logistic regression model, the vaccine's efficacy in protecting against Ebola virus was successfully inferred in humans.

NPJ VACCINES (2022)

Article Multidisciplinary Sciences

Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques

Laura Solforosi, Lea M. M. Costes, Jeroen T. B. M. Tolboom, Katherine McMahan, Tochi Anioke, David Hope, Tetyana Murdza, Michaela Sciacca, Emily Bouffard, Julia Barrett, Cindy Wu, Nicole Hachmann, Jessica Miller, Jingyou Yu, Xuan He, Catherine Jacob-Dolan, Sietske K. Rosendahl Huber, Liesbeth Dekking, Ronnie Chamanza, Ying Choi, Karin Feddes-de Boer, Dan H. Barouch, Hanneke Schuitemaker, Roland C. Zahn, Frank Wegmann

Summary: Using Omicron spike (S) encoding vaccines as boosters is a potential strategy to improve COVID-19 vaccine efficacy against Omicron. The authors found that both Wuhan-Hu-1-based Ad26.COV2.S or an Omicron-adapted booster vaccine provide robust immune responses and protection against Omicron in NHP.

NATURE COMMUNICATIONS (2023)

Article Immunology

Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2

Maarten Swart, Joan van der Lubbe, Sonja Schmit-Tillemans, Ella van Huizen, Johan Verspuij, Ana Izquierdo Gil, Ying Choi, Chenandly Daal, Aditya Perkasa, Adriaan de Wilde, Erwin Claassen, Rineke de Jong, Katrin E. Wiese, Lisette Cornelissen, Marieke van Es, Marjolein van Heerden, Eleni Kourkouta, Issam Tahiri, Michel Mulders, Jessica Vreugdenhil, Karin Feddes de Boer, Leacky Muchene, Jeroen Tolboom, Liesbeth Dekking, Jarek Juraszek, Jort Vellinga, Jerome Custers, Rinke Bos, Hanneke Schuitemaker, Frank Wegmann, Ramon Roozendaal, Harmjan Kuipers, Roland Zahn

Summary: Since the outbreak of SARS-CoV-2, several rapidly spreading variants of concern (VOC) have emerged. A single dose of Ad26.COV2.S has shown to protect against the Gamma and Delta variants in naive hamsters, supporting its efficacy in humans against these VOC. However, an Omicron BA.1-based booster does not improve immunogenicity and efficacy against Omicron BA.2 compared to an Ad26.COV2.S booster in hamsters with pre-existing immunity to SARS-CoV-2.

NPJ VACCINES (2023)

Article Immunology

Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models

Eirikur Saeland, Leslie van der Fits, Renske Bolder, Marjolein Heemskerk-van der Meer, Joke Drijver, Yolinda van Polanen, Cornelis Vaneman, Lisanne Tettero, Freek Cox, Jan Serroyen, Matthew J. Jorgensen, Johannes P. M. Langedijk, Hanneke Schuitemaker, Benoit Callendret, Roland C. Zahn

Summary: No licensed vaccine is available for respiratory syncytial virus (RSV) which causes severe respiratory disease. However, this study suggests that a combination of prefusion RSV F protein antigen and adenoviral vector encoding RSV preF protein can induce strong humoral and cellular immune responses, providing superior protection against RSV.

NPJ VACCINES (2023)

Article Immunology

RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models

Freek Cox, Eirikur Saeland, Anne Thoma, Ward van den Hoogen, Lisanne Tettero, Joke Drijver, Cornelis Vaneman, Yolinda van Polanen, Tina Ritschel, Arangassery Rosemary Bastian, Benoit Callendret, Roland Zahn, Leslie van der Fits

Summary: RSV is divided into two antigenic subtypes, RSV A and RSV B, based on variation in the G protein. Vaccines based on RSV A-based fusion protein have been shown to induce broad protective immune responses against both RSV A and RSV B subtypes in preclinical animal models, including through passive transfer of human antibodies.

VACCINES (2023)

No Data Available